A
Alcista
Alcista · 25%HOLX
$90.01
Precio del escenario
$76.010
+0.365 (+0.48%)Al cierre
Loading chart…
- Máximo
- 76.070
- Apertura
- 76.010
- Precio medio ponderado por volumen
- 76.03
- Volumen
- 102.03M
- Capitalización
- 17.32B
- Mínimo
- 76.000
- Importe
- 7.76B
- EV/EBITDA, TTM
- 11.25
Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm.
Análisis de IA of Hologic Inc (HOLX)
MantenerHologic Inc (HOLX) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. While the technical indicators are mildly positive, the lack of significant positive catalysts, a recent analyst downgrade, and declining financial metrics suggest a cautious approach. Holding the stock or exploring other opportunities may be more prudent.
Recomendaciones de analistas (19)
+2.04% de potencial alcista
Comprar
14 Comprar
5 Mantener
0 Vender
Actual: 76.01
Mínimo
76.00
Promedio
77.56
Máximo
79.00
Evercore ISI
In Line
$78
2026-01-05
Evercore ISI
2026-01-05
Precio objetivo
$78
In Line
BNP Paribas Exane
Neutral
$79
2025-11-21
BNP Paribas Exane
2025-11-21
Precio objetivo
$79
Neutral
Morgan Stanley
Equal Weight
$76
2025-11-10
Morgan Stanley
2025-11-10
Precio objetivo
$76
Equal Weight
Mizuho
Neutral
$78
2025-10-23
Mizuho
2025-10-23
Precio objetivo
$78
Neutral
Stephens
Equal Weight
$76
2025-10-22
Stephens
2025-10-22
Precio objetivo
$76
Equal Weight
Métricas de valoración
El PER previsto actual de Hologic Inc (HOLX) es 16.36, frente a su media de 5 años de 18.06.
Escenarios de precio de Alphio AI para HOLX
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con HOLX en cartera
Cronología de eventos
Noticias
2.004-07CNBCApple Shares Drop Nearly 4% Amid Engineering Setbacks for Foldable iPhone
8.504-07Yahoo FinanceHologic Acquired by Blackstone and TPG Funds
8.504-07NewsfilterHologic Completes Acquisition, Appoints New CEO
5.004-07moomooHOLOGIC INC NAMES JOSÉ (JOE) E. ALMEIDA AS NEW CEO, EFFECTIVE IMMEDIATELY
8.504-07moomooBLACKSTONE AND TPG FINALIZE HOLOGIC ACQUISITION
Preguntas frecuentes sobre HOLX, respondidas por Alphio AI
Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm. It operates in the Healthcare sector (X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPA industry).
Hologic Inc (HOLX) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. While the technical indicators are mildly positive, the lack of significant positive catalysts, a recent analyst downgrade, and declining financial metrics suggest a cautious approach. Holding the stock or exploring other opportunities may be more prudent.
19 analysts cover HOLX: 14 rate it Buy, 5 Hold and 0 Sell. The average price target is 77.56.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.